Search filters

Authors whose works are in public domain in at least one jurisdiction

List of works by Victoria S Sprung

Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.

scientific article published on 27 January 2017

Dissociation between exercise-induced reduction in liver fat and changes in hepatic and peripheral glucose homoeostasis in obese patients with non-alcoholic fatty liver disease

scientific article

Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle

article

Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition

scientific article published in January 2014

Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies

scientific article published on March 2013

Exercise training improves cutaneous microvascular function in nonalcoholic fatty liver disease

scientific article

Exercise training in polycystic ovarian syndrome enhances flow-mediated dilation in the absence of changes in fatness

scientific article published in December 2013

External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals.

scientific article published in November 2014

Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat

scientific article published on 01 June 2019

Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance.

scientific article published on 26 July 2012

Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive

scientific article published on 22 July 2020

Paulina is supported by:

About Paulina

Help